Published in Curr Med Res Opin on October 01, 2009
Incretin-based therapies. J Diabetes (2012) 1.48
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag (2010) 1.45
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther (2014) 1.16
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc (2010) 1.09
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol (2012) 1.05
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev (2014) 0.94
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr (2012) 0.94
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2010) 0.92
The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud (2011) 0.91
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med (2013) 0.91
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. Diabetes Metab J (2014) 0.89
The role of incretin therapy at different stages of diabetes. Rev Diabet Stud (2011) 0.89
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.89
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol (2014) 0.87
GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci (2015) 0.86
Choosing a gliptin. Indian J Endocrinol Metab (2011) 0.84
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetol Metab Syndr (2012) 0.84
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes (2015) 0.83
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging (2013) 0.83
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag (2010) 0.82
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res (2011) 0.82
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab (2016) 0.81
Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab (2015) 0.80
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS One (2015) 0.78
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes Metab Syndr Obes (2010) 0.77
Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes (2014) 0.77
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes (2011) 0.77
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J (2016) 0.77
Saxagliptin for type 2 diabetes. Diabetes Metab Syndr Obes (2010) 0.77
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Adv Ther (2015) 0.77
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vasc Health Risk Manag (2014) 0.76
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Ther Clin Risk Manag (2014) 0.76
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. Clinicoecon Outcomes Res (2015) 0.76
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open (2017) 0.75
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother (2011) 0.75
Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. Medicine (Baltimore) (2016) 0.75
A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes. P T (2010) 0.75
Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. Clin Diabetes (2014) 0.75
Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract (2013) 0.75
Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. Int J Endocrinol (2014) 0.75
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep (2017) 0.75
Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. Vasc Health Risk Manag (2010) 0.75
Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Med Sci Monit (2015) 0.75
Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study. Exp Ther Med (2016) 0.75
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. CPT Pharmacometrics Syst Pharmacol (2013) 0.75
Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Ther (2016) 0.75
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol (2016) 0.75
Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Des Devel Ther (2017) 0.75
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes (2017) 0.75
Primary prevention of cardiovascular disease in older adults in China. World J Clin Cases (2017) 0.75
Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther (2017) 0.75
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. Eur J Clin Pharmacol (2014) 0.75
UMLS concept indexing for production databases: a feasibility study. J Am Med Inform Assoc (2001) 9.02
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
Organization of heterogeneous scientific data using the EAV/CR representation. J Am Med Inform Assoc (1999) 6.97
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 6.67
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage (2001) 4.48
GEM: a proposal for a more comprehensive guideline document model using XML. J Am Med Inform Assoc (2000) 4.46
A microassay for cell-mediated immunity. Transplantation (1970) 4.29
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol (1999) 3.96
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cell Immunol (1973) 3.17
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Primary structure of major outer membrane protein II (ompA protein) of Escherichia coli K-12. Proc Natl Acad Sci U S A (1980) 2.64
Primary structure of major outer membrane protein I of Escherichia coli B/r. Proc Natl Acad Sci U S A (1979) 2.60
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Mirror movements in parkinsonism: evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry (2005) 2.35
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34
Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry (1999) 2.32
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Lower BMI cut-off value to define obesity in Hong Kong Chinese: an analysis based on body fat assessment by bioelectrical impedance. Br J Nutr (2001) 2.25
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab (2009) 2.19
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology (2012) 2.18
External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am (1997) 2.16
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen. J Exp Med (1972) 2.13
Simultaneous bilateral laser in situ keratomileusis: safety and efficacy. Ophthalmology (1999) 2.13
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med (1996) 2.11
Surface immunoglobulin-moieties on lymphoid cells. Exp Cell Res (1970) 2.09
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Heart (2007) 2.06
Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus. Proc Natl Acad Sci U S A (1982) 2.06
Preoperative serum hCG level and intraoperative failure of laparoscopic linear salpingostomy for ectopic pregnancy. Obstet Gynecol (1998) 2.03
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. Cancer Res (1967) 2.01
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res (2000) 1.97
Bupivacaine wound instillation via an electronic patient-controlled analgesia device and a double-catheter system does not decrease postoperative pain or opioid requirements after major abdominal surgery. Anesth Analg (2001) 1.96
Radioimmunological screening method for specific membrane proteins. Anal Biochem (1979) 1.96
Interactions between two different inhibitory systems in the human motor cortex. J Physiol (2001) 1.91
An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A (1995) 1.86
A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods (2001) 1.86
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab (2013) 1.85
Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology (1993) 1.83
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene (2010) 1.81
Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice. Int J Cancer (1973) 1.80
Cell surface localized IgM-kappa immunoglobulin reactivity in a case of chronic lymphocytic leukaemia. Clin Exp Immunol (1970) 1.80
Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA (1997) 1.78
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics (1997) 1.77
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation (1995) 1.73
LATE INTESTINAL STENOSIS FOLLOWING STRANGULATED HERNIA. Ann Surg (1928) 1.72
Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol (2001) 1.71
Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells. J Immunol (1979) 1.71
The lymphocyte response to primary Moloney sarcoma virus tumors in BALB-c mice. Definition of the active subpopulations at different times after infection. J Exp Med (1973) 1.68
Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther (1999) 1.67
Dextromethorphan decreases the excitability of the human motor cortex. Neurology (1998) 1.66
Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology (1997) 1.63
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett (1999) 1.62
Detection of cell surface antigens on monolayer cells. I. The application of immune adherence on a micro scale. Immunology (1970) 1.62
Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst (1966) 1.61
A clone-array pooled shotgun strategy for sequencing large genomes. Genome Res (2001) 1.60
Involvement of the human pedunculopontine nucleus region in voluntary movements. Neurology (2010) 1.60
Sensitivity and specificity of dipstick tests for rapid diagnosis of malaria in nonimmune travelers. J Clin Microbiol (1999) 1.59
Involvement of the human subthalamic nucleus in movement preparation. Neurology (2003) 1.59
Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology (2002) 1.59
Should peritoneal tears be routinely closed during laparoscopic total extraperitoneal repair of inguinal hernias? A reappraisal. Surg Endosc (2004) 1.59
Intracellular Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected from human subjects. Infect Immun (2001) 1.58
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology (1996) 1.55
Endoscopic sphincterotomy in patients with gallbladder in situ: the influence of periampullary duodenal diverticula. Surgery (1990) 1.55
The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.54
Nucleotide sequence of the gene for the peptidoglycan-associated lipoprotein of Escherichia coli K12. Eur J Biochem (1987) 1.53
Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci U S A (1998) 1.53
Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension (1995) 1.53
The primary structure of protein L16 located at the peptidyltransferase center of Escherichia coli ribosomes. FEBS Lett (1976) 1.53
Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst (1967) 1.52
Inflammatory pseudotumor of the liver. Report of the fine needle aspiration cytologic findings in a case initially misdiagnosed as malignant. Acta Cytol (1989) 1.51
Conditioned tumorigenicity of activated oncogenes. Cancer Res (1986) 1.51
Root gravitropism: an experimental tool to investigate basic cellular and molecular processes underlying mechanosensing and signal transmission in plants. Annu Rev Plant Biol (2002) 1.51
Induction of microsatellite instability by oxidative DNA damage. Proc Natl Acad Sci U S A (1998) 1.51
- cross-linking sites in human and bovine fibrin. Biochemistry (1971) 1.50
A single nuclease active site of the Escherichia coli RecBCD enzyme catalyzes single-stranded DNA degradation in both directions. J Biol Chem (2000) 1.49
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
A tissue-specific enhancer confers Pit-1-dependent morphogen inducibility and autoregulation on the pit-1 gene. Genes Dev (1993) 1.48